Latest News & Updates
The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.
Fats in blood and on the body increase men’s prostate cancer risk, two studies have found.
Two HER2-targeting regimens anchored by T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer in the MARIANNE trial, dealing a blow to efforts to move the drug into frontline settings.
Clonal Hematopoiesis in Normal Individuals Might Represent a New Way to Approach Blood Cancer Risk and Diagnosis
Cancers arise from multiple acquired mutations that presumably occur over many years, as shown in a number of models, particularly in colon cancer.
Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.
Latest Peer Exchange Discussions
Moderator Raoul S. Concepcion, MD, FACS, leads a discussion on the use of multiparametric MRI fusion biopsy as another strategy for detecting prostate cancer. View Now
In this segment, Warner K. Huh, MD, Michael J. Birrer, MD, PhD, Robert A. Burger, MD, FACOG, FACS, James Tate Thigpen, MD, and moderator Maurie Markman, MD, discuss the role of prophylactic oophorectomy for BRCA-positive women. View Now
In this segment, Benjamin P. Levy, MD, discusses the role of adjuvant chemotherapy versus neoadjuvant chemotherapy for patients with NSCLC undergoing surgical resection with curative intent. View Now
Daniel J. George, MD, describes the impact of skeletal-related events (SREs) in patients with mCRPC and discusses strategies for preventing SREs. George also discusses the use of Oncotype DX for risk stratification and agents currently in development for mCRPC. View Now
Most Popular Right Now
Online CME Activities